Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 4/20 | 0.39 |
| ▸ | HTR7 | P34969 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802535 | 0.93 | TRPV4 (0.42) | ALDH1A1GAATHRBHTR7LMNA | |
| SCHEMBL6798114 | 0.92 | GNRHR (0.42) | GAATHRBHTR7LMNATP53 | |
| SCHEMBL6800538 | 0.91 | THRB (0.41) | ALDH1A1GAATHRBLMNARXFP1 | |
| SCHEMBL6797472 | 0.90 | THRB (0.39) | ALDH1A1GAATHRBLMNARXFP1 | |
| SCHEMBL6801037 | 0.86 | THRB (0.41) | ALDH1A1GAATHRBLMNATP53 | |
| SCHEMBL6800733 | 0.85 | THRB (0.46) | ALDH1A1GAATHRBLMNATP53 | |
| SCHEMBL6800773 | 0.85 | HTR7 (0.44) | ALDH1A1GAAHTR7LMNAPIK3CA | |
| SCHEMBL6800569 | 0.85 | MEN1 (0.47) | ALDH1A1THRBLMNAMEN1KMT2A | |
| SCHEMBL6799753 | 0.83 | GRM5 (0.44) | GAATHRBLMNARXFP1 | |
| SCHEMBL6802963 | 0.83 | PIM1 (0.40) | PIK3CAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | claimed |
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1028950-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999021840-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | ALDH1A1 3064/4885GAA 1090/4885THRB 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.